The Hepatitis Drug Interactions website was launched in 2010. The website team is based at the University of Liverpool and has responsibility to constantly monitor and update the site’s content.
David Back (Liverpool)
Along with Saye, David provides the team’s strategic leadership. He gives a scientific lead to the development of website content, represents the website team at international conferences and events and helps shape the future development and direction of the resources we produce.
Saye Khoo (Liverpool)
Along with David, Saye provides the team’s strategic leadership. He gives a clinical lead to the development of website content and represents the website team at national and international meetings. He is particularly interested in harnessing the technology of the websites to continuously improve patient care.
Fiona Marra (Glasgow)
Principal Pharmacist and Lead for Content Development
Fiona is the responsible lead for assessing drug-drug interactions and predicting interactions using a mechanistic approach where clinical data is as yet unavailable. She draws on her clinical experience of treating HCV patients in Glasgow. Fiona contributes to the overall development and expansion of the website and teaches extensively on HCV related pharmacokinetics, representing the website team at international conferences and meetings.
Sara Gibbons (Liverpool)
Sara is responsible for the general administration of the website and manages and updates its content, ensuring quality and consistency are maintained.
Katie McAllister (Liverpool)
Business Development Manager
Katie is responsible for fundraising for the team and for developing partnerships and projects which support our mission and ethos. Please contact her at email@example.com if you are interested in supporting us or working with us.
Justin Chiong (Liverpool)
Justin is responsible for finance and analysing the websites’ performance. He also provides general administrative support to all aspects of the team’s activity.
Catia Marzolini (Basel)
Catia supports the prediction of drug-drug interactions where no clinical data is yet available using a mechanistic approach.